Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry

医学 哮喘 队列 内科学 优势比 队列研究 儿科
作者
P. Jane McDowell,Ron McDowell,John Busby,M. Chad Eastwood,Pujan H. Patel,David J. Jackson,Adel Hasan Mansur,Mitesh Patel,Hassan Burhan,Simon J Doe,Rekha Chaudhuri,Robin B Gore,James William Dodd,Deepak Subramanian,Thomas Brown,Liam Gabriel Heaney
出处
期刊:The European respiratory journal [European Respiratory Society]
卷期号:62 (6): 2300819-2300819 被引量:172
标识
DOI:10.1183/13993003.00819-2023
摘要

BACKGROUND: Novel biologic therapies have revolutionised the management of severe asthma with more ambitious treatment aims. Here we analyse the definition of clinical remission as a suggested treatment goal and consider the characteristics associated with clinical remission in a large, real-world severe asthma cohort. METHODS: This was a retrospective analysis of severe asthma patients registered in the UK Severe Asthma Registry (UKSAR) who met strict national access criteria for biologics. Patients had a pre-biologics baseline assessment and annual review. The primary definition of clinical remission applied included Asthma Control Questionnaire (ACQ)-5 <1.5 and no oral corticosteroids for disease control and forced expiratory volume in 1 s above lower limit of normal or no more than 100 mL less than baseline. RESULTS: 18.3% of patients achieved the primary definition of remission. The adjusted odds of remission on biologic therapy were 7.44 (95% CI 1.73-31.95)-fold higher in patients with type 2 (T2)-high biomarkers. The adjusted odds of remission were lower in patients who were female (OR 0.61, 95% CI 0.45-0.93), obese (OR 0.49, 95% CI 0.24-0.65) or had ACQ-5 ≥1.5 (OR 0.19, 95% CI 0.12-0.31) pre-biologic therapy. The likelihood of remission reduced by 14% (95% CI 0.76-0.97) for every 10-year increase in disease duration. 12-21% of the cohort attained clinical remission depending on the definition applied; most of those who did not achieve remission failed to meet multiple criteria. CONCLUSIONS: 18.3% of patients achieved the primary definition of clinical remission. Remission was more likely in T2-high biomarker patients with shorter duration of disease and less comorbidity. Further research on the optimum time to commence biologics in severe asthma is required.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Jason完成签到 ,获得积分10
刚刚
然目之绮发布了新的文献求助10
刚刚
cc完成签到,获得积分10
刚刚
Crazy_Runner发布了新的文献求助10
刚刚
faust0052完成签到 ,获得积分10
刚刚
岚天完成签到,获得积分10
1秒前
good233完成签到,获得积分10
1秒前
嘚儿塔发布了新的文献求助10
1秒前
cwx完成签到 ,获得积分10
1秒前
webmaster完成签到,获得积分10
2秒前
老爷爷遨游世界完成签到,获得积分10
2秒前
QAQ完成签到,获得积分10
2秒前
桐桐的应助被pan采纳,获得10
2秒前
2秒前
moonli完成签到,获得积分10
3秒前
mxdckd完成签到,获得积分10
3秒前
67号完成签到 ,获得积分10
3秒前
3秒前
Rony发布了新的文献求助10
4秒前
愉快惮的应助被butterfly采纳,获得10
5秒前
huanhuan完成签到,获得积分10
5秒前
思源的应助被司空之槐采纳,获得10
5秒前
葛甲率发布了新的文献求助10
5秒前
one星完成签到,获得积分10
5秒前
多多指教完成签到,获得积分10
5秒前
蒸包完成签到,获得积分10
5秒前
魔幻的咖啡豆完成签到 ,获得积分10
5秒前
于你无瓜完成签到 ,获得积分10
6秒前
风中雨兰完成签到 ,获得积分10
6秒前
6秒前
冷静剑成完成签到,获得积分10
7秒前
安夏完成签到,获得积分10
7秒前
在水一方的应助被zc采纳,获得10
7秒前
飞快的邴完成签到,获得积分10
7秒前
皮卡第的玫瑰完成签到,获得积分10
7秒前
7秒前
积极的怜南完成签到,获得积分10
7秒前
cdercder的应助被风吹麦浪采纳,获得10
8秒前
阿琦完成签到,获得积分10
8秒前
cdercder的应助被风吹麦浪采纳,获得10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159212
求助须知:如何正确求助?哪些是违规求助? 9554678
关于积分的说明 21720538
捐赠科研通 7748887
什么是DOI,文献DOI怎么找? 3427184
关于科研通互助平台的介绍 2552092
邀请新用户注册赠送积分活动 2471464